Skip to content
value.today

CV Sciences, Inc.: peers

Change the peers

CV Sciences, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

CV Sciences, Inc., Healthy Extracts Inc., Neurogene Inc., Resonate Blends, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

CV Sciences, Inc., Healthy Extracts Inc., TherapeuticsMD, Inc., Cosmos Holdings, Neurogene Inc., Rockwell Medical, Inc., Resonate Blends, Inc., Scynexis, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCV Sciences, Inc.base
CVSI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Healthy Extracts Inc.
HYEX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
TherapeuticsMD, Inc.
TXMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Cosmos Holdings
COSM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Neurogene Inc.
NGNE · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Rockwell Medical, Inc.
RMTI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Resonate Blends, Inc.
KOAN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Scynexis, Inc.
SCYX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$20 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one6th of 8$19 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one7th of 8$23 MOct 14, 2026 · Market data5th of 8$28 MOct 30, 2026 · Market data4th of 8$30 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8$32 MOct 16, 2026 · Market data2nd of 8$12 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one8th of 8$38 MOct 30, 2026 · Market data1st of 8$25 M8 ranked
Revenue (Better neither way: ranked highest first)$14 MFY2025 · SEC4th of 7$5 MFY2025 · SEC5th of 7$3 MFY2025 · SEC6th of 7$65 MFY2025 · SEC2nd of 7——$69 MFY2025 · SEC1st of 7$2 MFY2024 · SEC7th of 7$21 MFY2025 · SEC3rd of 7$14 M7 ranked
Net income (Higher is better)$-1 MFY2025 · SEC3rd of 8$-1 MFY2025 · SEC2nd of 8$-1 MFY2025 · SEC1st of 8$-19 MFY2025 · SEC7th of 8$-90 MFY2025 · SEC8th of 8$-5 MFY2025 · SEC5th of 8$-2 MFY2024 · SEC4th of 8$-9 MFY2025 · SEC6th of 8$-4 M8 ranked
Employees (Better neither way: ranked highest first)44December 31, 2025 · Profile3rd of 4————163December 31, 2025 · Profile1st of 4131March 16, 2026 · Profile2nd of 4————18March 1, 2026 · Profile4th of 4884 ranked
Growth
Market cap change, 30 days (Higher is better)——————————————-23.3%30 days to Oct 30, 2026 · Market dataonly one with it-23.3%—
Revenue growth (Higher is better)-12.2%FY2025 · SEC5th of 614th10th+45.0%FY2025 · SEC3rd of 683rd91st+71.6%FY2025 · SEC2nd of 689th94th+19.9%FY2025 · SEC4th of 668th79th————-31.8%FY2025 · SEC6th of 68th4th————+449.3%FY2025 · SEC1st of 699th99th+32.5%6 ranked
Revenue growth, 3 years a year (Higher is better)-5.2%FY2025 · SEC4th of 416th18th+26.1%FY2025 · SEC1st of 479th90th————+9.0%FY2025 · SEC2nd of 451st66th————-1.6%FY2025 · SEC3rd of 423rd27th————————+3.7%4 ranked
Margins and returns
Gross margin (Higher is better)49.0%FY2025 · SEC3rd of 535th62nd53.7%FY2025 · SEC2nd of 542nd67th————12.1%FY2025 · SEC5th of 55th10th————16.9%FY2025 · SEC4th of 57th16th65.3%FY2024 · SEC1st of 560th78th————49.0%5 ranked
Operating margin (Higher is better)-3.4%FY2025 · SEC1st of 653rd34th————-145.4%FY2025 · SEC6th of 619th8th-25.6%FY2025 · SEC3rd of 639th20th————-6.8%FY2025 · SEC2nd of 651st30th-89.5%FY2024 · SEC5th of 625th11th-78.0%FY2025 · SEC4th of 626th12th-51.8%6 ranked
Net margin (Higher is better)-7.0%FY2025 · SEC1st of 751st30th-19.5%FY2025 · SEC4th of 743rd22nd-18.9%FY2025 · SEC3rd of 743rd22nd-29.3%FY2025 · SEC5th of 739th18th————-7.7%FY2025 · SEC2nd of 750th29th-112.1%FY2024 · SEC7th of 721st9th-41.8%FY2025 · SEC6th of 733rd16th-19.5%7 ranked
Free cash flow margin (Higher is better)-3.8%FY2025 · SEC2nd of 446th27th————————-13.0%FY2025 · SEC3rd of 441st20th————-1.7%FY2025 · SEC1st of 449th30th-54.2%FY2024 · SEC4th of 427th12th————-8.4%4 ranked
Return on equity (Higher is better)-58.7%FY2025 · SEC6th of 739th16th-7.3%FY2025 · SEC2nd of 768th35th-2.1%FY2025 · SEC1st of 771st40th-89.1%FY2025 · SEC7th of 728th12th-31.4%FY2025 · SEC5th of 753rd23rd-15.3%FY2025 · SEC3rd of 763rd30th————-16.5%FY2025 · SEC4th of 762nd29th-16.5%7 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————————6.9×price Oct 14, 2026 · Market data1st of 464th84th0.4×price Oct 30, 2026 · Market data4th of 46th11th————0.4×price Oct 16, 2026 · Market data3rd of 47th14th————1.9×price Oct 30, 2026 · Market data2nd of 431st46th1.2×4 ranked
Price to book (Better neither way: ranked highest first)————————0.8×price Oct 14, 2026 · Market data3rd of 416th16th1.5×price Oct 30, 2026 · Market data1st of 431st37th————0.9×price Oct 16, 2026 · Market data2nd of 416th16th————0.8×price Oct 30, 2026 · Market data4th of 415th14th0.9×4 ranked
Free cash flow yield (Higher is better)————————————-30.2%price Oct 30, 2026 · Market data2nd of 326th11th————-3.7%price Oct 16, 2026 · Market data1st of 357th29th————-142.0%price Oct 30, 2026 · Market data3rd of 34th1st-30.2%3 ranked
Financial strength
Debt to equity (Lower is better)1.1×FY2025 · SEC3rd of 377th71st————————0.2×FY2025 · SEC1st of 333rd24th————0.2×FY2025 · SEC2nd of 335th26th————————0.2×3 ranked
Interest cover (Higher is better)————————-439.0×FY2025 · SEC2nd of 27th2nd-8.8×FY2025 · SEC1st of 244th24th————————————————-223.9×2 ranked
Piotroski F-score (Higher is better)6 of 9FY2025 · SEC1st of 3————5 of 9FY2025 · SEC2nd of 3——3 of 9FY2025 · SEC3rd of 3————5.0 of 93 ranked
Scorecard
Scorecard (Higher is better)3 of 15FY2025 · Scorecard7th of 85 of 10FY2025 · Scorecard1st of 85 of 17FY2025 · Scorecard5th of 87 of 22FY2025 · Scorecard3rd of 81 of 8FY2025 · Scorecard8th of 87 of 22FY2025 · Scorecard3rd of 82 of 8FY2024 · Scorecard6th of 86 of 17FY2025 · Scorecard2nd of 831% passed8 ranked
Valuation checks (Higher is better)————1 of 4FY2025 · Scorecard4th of 42 of 5FY2025 · Scorecard1st of 4——2 of 5FY2025 · Scorecard1st of 4——2 of 5FY2025 · Scorecard1st of 440% passed4 ranked
Growth checks (Higher is better)1 of 6FY2025 · Scorecard6th of 85 of 5FY2025 · Scorecard1st of 82 of 3FY2025 · Scorecard2nd of 84 of 6FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard8th of 81 of 6FY2025 · Scorecard6th of 81 of 2FY2024 · Scorecard5th of 82 of 3FY2025 · Scorecard2nd of 858% passed8 ranked
Profitability checks (Higher is better)1 of 5FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard5th of 80 of 5FY2025 · Scorecard5th of 80 of 5FY2025 · Scorecard5th of 80 of 3FY2025 · Scorecard5th of 81 of 5FY2025 · Scorecard2nd of 81 of 4FY2024 · Scorecard1st of 81 of 5FY2025 · Scorecard2nd of 810% passed8 ranked
Financial health checks (Higher is better)1 of 3FY2025 · Scorecard3rd of 80 of 2FY2025 · Scorecard7th of 81 of 4FY2025 · Scorecard5th of 81 of 5FY2025 · Scorecard6th of 81 of 2FY2025 · Scorecard2nd of 83 of 5FY2025 · Scorecard1st of 80 of 2FY2024 · Scorecard7th of 81 of 3FY2025 · Scorecard3rd of 829% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard2nd of 6——1 of 1FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard2nd of 6——0 of 1FY2025 · Scorecard2nd of 60% passed6 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)————32.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 57.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5115.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 57.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 5——46.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 532.1%5 ranked
Institutions holding (Better neither way: ranked highest first)————462026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 51322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 5——422026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5425 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————-2.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 3+1.0 pp2026-Q2 against 2026-Q1 · 13F1st of 3-22.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 3——————-2.3 pp3 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = CV Sciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Healthy Extracts Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; TherapeuticsMD, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cosmos Holdings: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Neurogene Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Rockwell Medical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Resonate Blends, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Scynexis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
CV Sciences, Inc.-3.4%FY2025
53rd percentile in Healthcaremedian -7.7%, 674 companies
34th percentile in USAmedian 3.5%, 2,594 companies
Healthy Extracts Inc.———
TherapeuticsMD, Inc.-145.4%FY2025
19th percentile in Healthcaremedian -7.7%, 674 companies
8th percentile in USAmedian 3.5%, 2,594 companies
Cosmos Holdings-25.6%FY2025
39th percentile in Healthcaremedian -7.7%, 674 companies
20th percentile in USAmedian 3.5%, 2,594 companies
Neurogene Inc.———
Rockwell Medical, Inc.-6.8%FY2025
51st percentile in Healthcaremedian -7.7%, 674 companies
30th percentile in USAmedian 3.5%, 2,594 companies
Resonate Blends, Inc.-89.5%FY2024
25th percentile in Healthcaremedian -7.7%, 674 companies
11th percentile in USAmedian 3.5%, 2,594 companies
Scynexis, Inc.-78.0%FY2025
26th percentile in Healthcaremedian -7.7%, 674 companies
12th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$25 M$51 M$76 M$101 M20102012201420162018202020222024CV Sciences, Inc. $14 MHealthy Extracts Inc. $5 MTherapeuticsMD, Inc. $3 MCosmos Holdings $65 MNeurogene Inc. $1 MRockwell Medical, Inc. $69 MResonate Blends, Inc. $2 MScynexis, Inc. $21 M

Rank in the group

1st2nd3rd4th5th6th7th8th201120122013201420152016201720182019202020212022202320242025CV Sciences, Inc.: 4th of 6 in 2014CV Sciences, Inc.: 3rd of 6 in 2015CV Sciences, Inc.: 3rd of 7 in 2016CV Sciences, Inc.: 3rd of 7 in 2017CV Sciences, Inc.: 2nd of 8 in 2018CV Sciences, Inc.: 2nd of 7 in 2019CV Sciences, Inc.: 4th of 5 in 2020CV Sciences, Inc.: 3rd of 6 in 2021CV Sciences, Inc.: 4th of 7 in 2022CV Sciences, Inc.: 3rd of 6 in 2023CV Sciences, Inc.: 3rd of 8 in 2024CV Sciences, Inc.: 4th of 6 in 2025CV Sciences, Inc.Healthy Extracts Inc.: 6th of 6 in 2015Healthy Extracts Inc.: 7th of 7 in 2016Healthy Extracts Inc.: 7th of 7 in 2017Healthy Extracts Inc.: 8th of 8 in 2018Healthy Extracts Inc.: 6th of 7 in 2019Healthy Extracts Inc.: 5th of 5 in 2020Healthy Extracts Inc.: 5th of 6 in 2021Healthy Extracts Inc.: 6th of 7 in 2022Healthy Extracts Inc.: 4th of 6 in 2023Healthy Extracts Inc.: 5th of 8 in 2024Healthy Extracts Inc.: 5th of 6 in 2025Healthy Extracts Inc.TherapeuticsMD, Inc.: 2nd of 2 in 2011TherapeuticsMD, Inc.: 2nd of 2 in 2012TherapeuticsMD, Inc.: 3rd of 5 in 2013TherapeuticsMD, Inc.: 2nd of 6 in 2014TherapeuticsMD, Inc.: 2nd of 6 in 2015TherapeuticsMD, Inc.: 2nd of 7 in 2016TherapeuticsMD, Inc.: 4th of 7 in 2017TherapeuticsMD, Inc.: 5th of 8 in 2018TherapeuticsMD, Inc.: 3rd of 7 in 2019TherapeuticsMD, Inc.: 1st of 5 in 2020TherapeuticsMD, Inc.: 2nd of 7 in 2022TherapeuticsMD, Inc.: 5th of 6 in 2023TherapeuticsMD, Inc.: 7th of 8 in 2024TherapeuticsMD, Inc.: 6th of 6 in 2025TherapeuticsMD, Inc.Cosmos Holdings: 4th of 5 in 2013Cosmos Holdings: 5th of 6 in 2014Cosmos Holdings: 4th of 7 in 2016Cosmos Holdings: 2nd of 7 in 2017Cosmos Holdings: 3rd of 8 in 2018Cosmos Holdings: 4th of 7 in 2019Cosmos Holdings: 3rd of 5 in 2020Cosmos Holdings: 2nd of 6 in 2021Cosmos Holdings: 3rd of 7 in 2022Cosmos Holdings: 2nd of 6 in 2023Cosmos Holdings: 2nd of 8 in 2024Cosmos Holdings: 2nd of 6 in 2025Cosmos HoldingsNeurogene Inc.: 4th of 8 in 2018Neurogene Inc.: 8th of 8 in 2024Neurogene Inc.Rockwell Medical, Inc.: 1st of 2 in 2011Rockwell Medical, Inc.: 1st of 2 in 2012Rockwell Medical, Inc.: 1st of 5 in 2013Rockwell Medical, Inc.: 1st of 6 in 2014Rockwell Medical, Inc.: 1st of 6 in 2015Rockwell Medical, Inc.: 1st of 7 in 2016Rockwell Medical, Inc.: 1st of 7 in 2017Rockwell Medical, Inc.: 1st of 8 in 2018Rockwell Medical, Inc.: 1st of 7 in 2019Rockwell Medical, Inc.: 2nd of 5 in 2020Rockwell Medical, Inc.: 1st of 6 in 2021Rockwell Medical, Inc.: 1st of 7 in 2022Rockwell Medical, Inc.: 1st of 6 in 2023Rockwell Medical, Inc.: 1st of 8 in 2024Rockwell Medical, Inc.: 1st of 6 in 2025Rockwell Medical, Inc.Resonate Blends, Inc.: 5th of 5 in 2013Resonate Blends, Inc.: 6th of 6 in 2014Resonate Blends, Inc.: 4th of 6 in 2015Resonate Blends, Inc.: 5th of 7 in 2016Resonate Blends, Inc.: 5th of 7 in 2017Resonate Blends, Inc.: 6th of 8 in 2018Resonate Blends, Inc.: 5th of 7 in 2019Resonate Blends, Inc.: 6th of 6 in 2021Resonate Blends, Inc.: 7th of 7 in 2022Resonate Blends, Inc.: 6th of 6 in 2023Resonate Blends, Inc.: 6th of 8 in 2024Resonate Blends, Inc.Scynexis, Inc.: 2nd of 5 in 2013Scynexis, Inc.: 3rd of 6 in 2014Scynexis, Inc.: 5th of 6 in 2015Scynexis, Inc.: 6th of 7 in 2016Scynexis, Inc.: 6th of 7 in 2017Scynexis, Inc.: 7th of 8 in 2018Scynexis, Inc.: 7th of 7 in 2019Scynexis, Inc.: 4th of 6 in 2021Scynexis, Inc.: 5th of 7 in 2022Scynexis, Inc.: 4th of 8 in 2024Scynexis, Inc.: 3rd of 6 in 2025Scynexis, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCV Sciences, Inc.Healthy Extracts Inc.TherapeuticsMD, Inc.Cosmos HoldingsNeurogene Inc.Rockwell Medical, Inc.Resonate Blends, Inc.Scynexis, Inc.
2025$14 MSEC4th$5 MSEC5th$3 MSEC6th$65 MSEC2nd—$69 MSEC1st—$21 MSEC3rd
2024$16 MSEC3rd$3 MSEC5th$2 MSEC7th$54 MSEC2nd$1 MSEC8th$101 MSEC1st$2 MSEC6th$4 MSEC4th
2023$16 MSEC3rd$2 MSEC4th$1 MSEC5th$53 MSEC2nd—$84 MSEC1st$0 MSEC6th—
2022$16 MSEC4th$2 MSEC6th$70 MSEC2nd$50 MSEC3rd—$73 MSEC1st$0 MSEC7th$5 MSEC5th
2021$20 MSEC3rd$2 MSEC5th—$56 MSEC2nd—$62 MSEC1st$0 MSEC6th$13 MSEC4th
2020$24 MSEC4th$1 MSEC5th$65 MSEC1st$55 MSEC3rd—$62 MSEC2nd——
2019$54 MSEC2nd$1 MSEC6th$50 MSEC3rd$40 MSEC4th—$61 MSEC1st$1 MSEC5th$0 MSEC7th
2018$48 MSEC2nd$0 MSEC8th$16 MSEC5th$37 MSEC3rd$25 MSEC4th$63 MSEC1st$1 MSEC6th$0 MSEC7th
2017$21 MSEC3rd$0 MSEC7th$17 MSEC4th$30 MSEC2nd—$57 MSEC1st$1 MSEC5th$0 MSEC6th
2016$11 MSEC3rd$0 MSEC7th$19 MSEC2nd$7 MSEC4th—$53 MSEC1st$0 MSEC5th$0 MSEC6th
2015$12 MSEC3rd$0 MSEC6th$20 MSEC2nd——$55 MSEC1st$0 MSEC4th$0 MSEC5th
2014$10 MSEC4th—$15 MSEC2nd$8 MSEC5th—$54 MSEC1st$0 MSEC6th$12 MSEC3rd

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of CV Sciences, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Healthy Extracts Inc.HYEX · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (last known, Jul 30, 2023) · revenue $5 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • TherapeuticsMD, Inc.TXMD · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $23 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $23 M (Oct 14, 2026) · revenue $3 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Cosmos HoldingsCOSM · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $28 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $28 M (Oct 30, 2026) · revenue $65 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Neurogene Inc.NGNE · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $30 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $30 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Rockwell Medical, Inc.RMTI · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $32 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $32 M (Oct 16, 2026) · revenue $69 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Resonate Blends, Inc.KOAN · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $12 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $12 M (last known, Jan 7, 2022) · revenue $2 M (year to December 2024)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Scynexis, Inc.SCYX · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $38 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $38 M (Oct 30, 2026) · revenue $21 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Bonk, Inc.BNKK · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $10 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $10 M (Oct 30, 2026) · revenue $2 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    + Add
  • Elite Pharmaceuticals, Inc.ELTP · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $42 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $42 M (last known, Jan 7, 2022) · revenue $149 M (year to March 2026)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • Weed Inc.BUDZ · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $9 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $9 M (last known, Jul 30, 2023)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • Medmen Enterprises Inc.MMEN.CN · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $21 M market cap against $20 M · Same country: USA
    Market cap $21 M (last known, Jan 5, 2024)
    95 of 100 (industry or sector 50 + size 30 + country 15)
    + Add
  • Cansortium Inc.TIUM-U.CN · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $19 M market cap against $20 M · Same country: USA
    Market cap $19 M (last known, Jan 5, 2024)
    95 of 100 (industry or sector 50 + size 30 + country 15)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.